Conexeu Sciences Inc. director Ana Lucia Bastiani-Posner reported her initial holdings of stock options. She holds options to buy 50,000 shares of common stock at an exercise price of $2.30 per share, expiring on February 9, 2031.
The footnote explains these options were granted on February 9, 2026 and vest over 12 months, with 25% of the grant vesting at three, six, nine and twelve months from the grant date. This filing is a baseline disclosure of her derivative equity position rather than a new market transaction.
Conexeu Sciences Inc. director and 10% owner Lynn Sebastian Purcell, through OnePointTwo Capital Ventures LLC, reported significant indirect insider activity in common stock and warrants on 2026-06-18. The LLC bought 202,500 shares of common stock at $0.80 per share, bringing its indirect common stock holdings to 2,734,240 shares. It also exercised warrants for 202,500 underlying common shares at an exercise price of $0.80 and separately bought 202,500 additional warrants at $0.001 per warrant, each exercisable for common stock at $2.30 per share, leaving 625,000 warrants indirectly held.
Conexeu Sciences Inc. ten percent owner Wright Michael G., through N3GU Investments LLC, exercised derivative securities to acquire 250,000 shares of Common Stock at $0.001 per share. Following this transaction, N3GU Investments LLC indirectly holds 2,148,048 Common shares. The Performance Warrants were originally granted for services, totaling 900,000, of which 650,000 have vested; the remaining 250,000 will vest and be exercisable when the company submits a 510(k) application to the U.S. Food and Drug Administration.
Conexeu Sciences Inc. registers 9,481,123 shares of Common Stock via a prospectus supplement to its Form S-1. This supplement incorporates and attaches the Company’s Form 8-K (June 9, 2026) and Form 10-Q (quarter ended April 30, 2026).
The supplement states the Company’s shares trade on Nasdaq under the symbol CNXU and cites a closing price of $9.82 on June 15, 2026. The filing discloses recent warrant activity: issuance and exercises tied to an incentive program and incremental issuances that affected shares outstanding.
Shares outstanding were 26,758,330 as of June 10, 2026. The supplement updates the Prospectus and must be read with the Prospectus for full terms and risk disclosures.
Conexeu Sciences Inc. (CNXU) reported larger losses as it builds out its regenerative medicine platform. For the quarter ended April 30, 2026, the company recorded a net loss of $2,304,283, and a six‑month net loss of $4,023,106, driven mainly by consulting, R&D and management compensation expenses of over $4.1M for the six‑month period.
Total assets were $8,199,679, including cash and cash equivalents of $6,848,064, funded largely through equity financings and a warrant inducement program. Management disclosed substantial doubt about the company’s ability to continue as a going concern without additional financing. Subsequent events include a Nasdaq listing under the symbol CNXU and further warrant exercises.
Conexeu Sciences Inc. reported the cash exercise of common stock purchase warrants and related share issuances. On June 4, 2026, the company issued 416,667 common shares for gross proceeds of about $166,667 under a warrant exercise incentive program and granted 416,667 new Incentive Warrants.
The Incentive Warrants allow holders to buy one additional share each at $2.30 for 36 months. After this exercise, 410,338 Program Warrants remained outstanding and common shares outstanding were 26,658,330. On June 8, 2026, Conexeu issued 100,000 Performance Warrant Shares at $0.001 per share, raising $100 and bringing total common shares outstanding to 26,758,330.
Conexeu Sciences Inc. insider entity N3GU Investments LLC, over which reporting person Michael G. Wright has sole voting and dispositive power, exercised 400,000 Performance Warrants to acquire 400,000 shares of Common Stock at $0.001 per share, all held indirectly.
Following the transactions, N3GU Investments LLC indirectly held 1,898,048 shares of Common Stock and 500,000 remaining Performance Warrants. The original grant covered 900,000 Performance Warrants, with future vesting tied to an >$80,000,000 market capitalization milestone and submission of a 510(k) application to the U.S. Food and Drug Administration.
Conexeu Sciences Inc. insider Michael G. Wright filed an initial Form 3 showing his beneficial ownership in CNXU. He reports indirect ownership of 1,498,048 shares of common stock through N3GU Investments LLC, over which he has sole voting and dispositive power, and direct ownership of 750,000 common shares.
Wright also holds derivative securities: 900,000 Performance Warrants with a $0.001 exercise price expiring on June 5, 2030, 78,595 Warrants with a $0.80 exercise price expiring on January 21, 2027, and 50,000 Stock Options with a $0.40 exercise price expiring on June 9, 2030. The stock options and standard warrants vested immediately on their respective grant dates.
Of the Performance Warrants, 150,000 have vested. The remaining 750,000 will vest in three 250,000-warrant tranches tied to specific milestones, including a North American stock exchange listing, a period of at least 20 consecutive trading days at a market capitalization above $80,000,000, and submission of a 510(k) application to the U.S. Food and Drug Administration.